Concert Pharmaceuticals Inc (NASDAQ:CNCE) Director Ronald W. Barrett sold 14,156 shares of the stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $24.70, for a total value of $349,653.20. Following the transaction, the director now owns 3,539 shares of the company’s stock, valued at $87,413.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) traded up $0.04 during midday trading on Friday, reaching $24.90. The company had a trading volume of 382,775 shares, compared to its average volume of 248,143. Concert Pharmaceuticals Inc has a 1 year low of $7.11 and a 1 year high of $26.37.

A number of hedge funds and other institutional investors have recently modified their holdings of CNCE. Vanguard Group Inc. boosted its position in Concert Pharmaceuticals by 6.1% during the first quarter. Vanguard Group Inc. now owns 681,712 shares of the biotechnology company’s stock valued at $11,630,000 after purchasing an additional 38,892 shares during the last quarter. Geode Capital Management LLC boosted its position in Concert Pharmaceuticals by 0.6% during the first quarter. Geode Capital Management LLC now owns 142,740 shares of the biotechnology company’s stock valued at $2,435,000 after purchasing an additional 838 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Concert Pharmaceuticals by 143.2% during the first quarter. Goldman Sachs Group Inc. now owns 32,349 shares of the biotechnology company’s stock valued at $552,000 after purchasing an additional 19,046 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Concert Pharmaceuticals by 47.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 32,122 shares of the biotechnology company’s stock valued at $449,000 after buying an additional 10,400 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Concert Pharmaceuticals by 8.0% in the second quarter. Rhumbline Advisers now owns 20,253 shares of the biotechnology company’s stock valued at $283,000 after buying an additional 1,500 shares during the last quarter. 65.36% of the stock is owned by hedge funds and other institutional investors.

A number of research firms recently issued reports on CNCE. Zacks Investment Research upgraded Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 10th. TheStreet raised Concert Pharmaceuticals from a “d” rating to a “c+” rating in a research report on Wednesday, November 29th. HC Wainwright reissued a “buy” rating and set a $21.00 price target on shares of Concert Pharmaceuticals in a research report on Friday, November 10th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $30.00 price target on shares of Concert Pharmaceuticals in a research report on Sunday, October 22nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. Concert Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $23.00.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/12/08/concert-pharmaceuticals-inc-cnce-director-ronald-w-barrett-sells-14156-shares-of-stock.html.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Receive News & Ratings for Concert Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.